A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
293 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Local Institution - 0129
Mar del Plata, Buenos Aires, Argentina
- Local Institution - 0061
Pergamino, Buenos Aires, Argentina
- Local Institution - 0153
Parana, Córdoba Province, Argentina
- Local Institution - 0393
Río Cuarto, Córdoba Province, Argentina
- Local Institution - 0083
Viedma, Río Negro Province, Argentina
- Local Institution - 0077
Buenos Aires, Argentina
- Local Institution - 0178
Buenos Aires, Argentina
- Local Institution - 0185
Buenos Aires, Argentina
- Local Institution - 0369
La Rioja, Argentina
- Local Institution - 0394
San Juan, Argentina
- Local Institution - 0152
Gosford, New South Wales, Australia
- Local Institution - 0091
Lismore, New South Wales, Australia
- Local Institution - 0132
Wahroonga, New South Wales, Australia
- Local Institution - 0127
Westmead, New South Wales, Australia
- Local Institution - 0006
South Brisbane, Queensland, Australia
- Local Institution - 0084
Woolloongabba, Queensland, Australia
- Local Institution - 0010
North Adelaide, South Australia, Australia
- Local Institution - 0379
Ballarat, Victoria, Australia
- Local Institution - 0040
Frankston, Victoria, Australia
- Local Institution - 0032
Malvern, Victoria, Australia
- Local Institution - 0118
Linz, Upper Austria, Austria
- Local Institution - 0038
Salzburg, Austria
- Local Institution - 0131
Vienna, Austria
- Local Institution - 0157
Vienna, Austria
- Local Institution - 0122
Anderlecht, Brussels Capital, Belgium
- Local Institution - 0121
Bruges, Belgium
- Local Institution - 0114
Ghent, Belgium
- Local Institution - 0162
Ghent, Belgium
- Local Institution - 0137
Turnhout, Belgium
- Local Institution - 0029
Wilrijk, Belgium
- Local Institution - 0022
Belo Horizonte, Minas Gerais, Brazil
- Local Institution - 0097
Belo Horizonte, Minas Gerais, Brazil
- Local Institution - 0082
Curitiba, Paraná, Brazil
- Local Institution - 0100
Curitiba, Paraná, Brazil
- Local Institution - 0321
Natal, Rio Grande do Norte, Brazil
- Local Institution - 0058
Ijuí, Rio Grande do Sul, Brazil
- Local Institution - 0056
Porto Alegre, Rio Grande do Sul, Brazil
- Local Institution - 0057
Porto Alegre, Rio Grande do Sul, Brazil
- Local Institution - 0063
Porto Alegre, Rio Grande do Sul, Brazil
- Local Institution - 0086
Campinas, São Paulo, Brazil
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Feb 2020
- Primary completion
- 1 Jun 2023
- Completion
- 25 Jun 2024
- Last update posted
- 12 Jun 2025
- Registered enrollment
- 1,030
- Registry id
- NCT04100018
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.